ES2034891B1 - Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas. - Google Patents

Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.

Info

Publication number
ES2034891B1
ES2034891B1 ES9101859A ES9101859A ES2034891B1 ES 2034891 B1 ES2034891 B1 ES 2034891B1 ES 9101859 A ES9101859 A ES 9101859A ES 9101859 A ES9101859 A ES 9101859A ES 2034891 B1 ES2034891 B1 ES 2034891B1
Authority
ES
Spain
Prior art keywords
nanocapsules
nanoparticles
chemically
preparing
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES9101859A
Other languages
English (en)
Other versions
ES2034891A1 (es
Inventor
Valdivia F Javier Galan
Mas Jose Alberto Vallet
Michael V W Bergamini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Cusi SA
Original Assignee
Laboratorios Cusi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Cusi SA filed Critical Laboratorios Cusi SA
Priority to ES9101859A priority Critical patent/ES2034891B1/es
Priority to DE4128910A priority patent/DE4128910A1/de
Priority to AT92202434T priority patent/ATE150642T1/de
Priority to EP92202434A priority patent/EP0529711B1/en
Priority to JP4212681A priority patent/JP2542149B2/ja
Publication of ES2034891A1 publication Critical patent/ES2034891A1/es
Application granted granted Critical
Publication of ES2034891B1 publication Critical patent/ES2034891B1/es
Priority to US08/309,797 priority patent/US5705196A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/783—Organic host/matrix, e.g. lipid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/832—Nanostructure having specified property, e.g. lattice-constant, thermal expansion coefficient
    • Y10S977/835—Chemical or nuclear reactivity/stability of composition or compound forming nanomaterial
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/832—Nanostructure having specified property, e.g. lattice-constant, thermal expansion coefficient
    • Y10S977/835—Chemical or nuclear reactivity/stability of composition or compound forming nanomaterial
    • Y10S977/836—Chemical or nuclear reactivity/stability of composition or compound forming nanomaterial having biological reactive capability
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/84—Manufacture, treatment, or detection of nanostructure
    • Y10S977/90—Manufacture, treatment, or detection of nanostructure having step or means utilizing mechanical or thermal property, e.g. pressure, heat

Abstract

PROCEDIMIENTO DE ELABORACION EN CONTINUO DE SISTEMAS COLOIDALES DISPERSOS, EN FORMA DE NANOCAPSULAS O NANOPARTICULAS. COMPRENDE: (1) PREPARAR UNA FASE ACUOSA CONTENIENDO AGENTES TENSOACTIVOS, SUSPENSORES Y, OPCIONALMENTE, UNA SUSTANCIA QUIMICA O BIOLOGICAMENTE ACTIVA; (2) PREPARAR UNA FASE ORGANICA CONTENIENDO UN POLIMERO O MONOMERO BIOCMPATIBLE Y, OPCIONALMENTE, UN LIPIDO O UNA SUSTANCIA QUIMICA O BIOLOGICAMENTE ACTIVA; (3) MEZCLAR AMBAS FASES EN FORMA CONTINUA EN UNA RELACION DE FASES Y VOLUMEN MEDIO CONSTANTE, RETIRANDO CONTINUAMENTE A SUSPENSION COLOIDAL RECIEN FORMADA; (4) ELIMINAR DE FORMA CONTINUA EL DISOLVENTE DE LA SUSPENSION COLOIDAL; Y (5) ELIMINAR POR COMPLETO EL DISOLVENTE ORGANICO Y PARTE O TODA EL AGUA PARA OBTENER LA CONCENTRACION DESEADA DE NANOESFERAS O EL PRODUCTO SECO. APLICACION EN BIOMEDICINA, FARMACIA, MEDICINA, COSMETICA, INDUSTRIA QUIMICA, AGRICULTURA Y VETERINARIA, ETC.
ES9101859A 1991-08-08 1991-08-08 Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas. Expired - Lifetime ES2034891B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES9101859A ES2034891B1 (es) 1991-08-08 1991-08-08 Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
DE4128910A DE4128910A1 (de) 1991-08-08 1991-08-30 Verfahren zur kontinuierlichen herstellung feinverteilter kolloidsysteme in form von nanokapseln oder nanopartikeln
AT92202434T ATE150642T1 (de) 1991-08-08 1992-08-05 Verfahren zur kontinuierlichen herstellung von dispersen kolloide-systemen in form von nanokapseln oder nanopartikeln
EP92202434A EP0529711B1 (en) 1991-08-08 1992-08-05 Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles
JP4212681A JP2542149B2 (ja) 1991-08-08 1992-08-10 ナノカプセルあるいはナノ粒子の分散コロイダル系の連続製造方法
US08/309,797 US5705196A (en) 1991-08-08 1994-09-21 Process of continuous preparation of disperse colloidal systems in the form of nanocapsules or nanoparticles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES9101859A ES2034891B1 (es) 1991-08-08 1991-08-08 Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.

Publications (2)

Publication Number Publication Date
ES2034891A1 ES2034891A1 (es) 1993-04-01
ES2034891B1 true ES2034891B1 (es) 1993-12-16

Family

ID=8273277

Family Applications (1)

Application Number Title Priority Date Filing Date
ES9101859A Expired - Lifetime ES2034891B1 (es) 1991-08-08 1991-08-08 Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.

Country Status (6)

Country Link
US (1) US5705196A (es)
EP (1) EP0529711B1 (es)
JP (1) JP2542149B2 (es)
AT (1) ATE150642T1 (es)
DE (1) DE4128910A1 (es)
ES (1) ES2034891B1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ES2078190B1 (es) * 1994-05-20 1996-08-01 Cusi Lab Procedimiento para el recubrimiento de goticulas o particulas de tamaño nanometrico.
WO1996020698A2 (en) * 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
ES2177592T3 (es) * 1995-07-05 2002-12-16 Europ Economic Community Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
EP1135682B1 (en) 1998-11-30 2007-07-11 Nanosphere, Inc. Nanoparticles with polymer shells
EP1144105B1 (de) * 1998-12-11 2002-09-25 Henkel Kommanditgesellschaft auf Aktien Verfahren zur herstellung von nanopartikeldispersionen
GB9919693D0 (en) * 1999-08-19 1999-10-20 Rhone Poulenc Rorer Ltd Process
FR2805761B1 (fr) 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
CA2309575A1 (en) * 2000-05-26 2001-11-26 James E. Guillet Internally cross-linked macromolecules
EP1401399A2 (en) * 2001-06-22 2004-03-31 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
CN1688275B (zh) * 2002-09-11 2012-05-30 田边三菱制药株式会社 微球的制备方法
US7112620B2 (en) * 2002-10-18 2006-09-26 Albright Robert L Hemocompatible polymer systems & related methods
JP4341238B2 (ja) * 2002-12-16 2009-10-07 日油株式会社 繊維加工方法および繊維
WO2005016976A2 (en) * 2003-05-27 2005-02-24 Albright Robert L Hemocompatible polymer systems and related methods
EP1652515A1 (en) * 2003-08-06 2006-05-03 Eisai Co., Ltd. Process for producing drug ultramicroparticle and apparatus therefor
US7714015B2 (en) * 2003-08-07 2010-05-11 Lil Brat Pharmaceuticals Of Marlette, Mi Method and composition for treating sunburned skin
EP1730516A1 (en) * 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
EP1674081A1 (de) * 2004-12-23 2006-06-28 KTB Tumorforschungsgesellschaft mbH Herstellung von lipidbasierten Nanopartikeln unter Einsatz einer dualen asymmetrischen Zentrifuge
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
US20100119612A1 (en) * 2007-04-17 2010-05-13 Bend Research, Inc Nanoparticles comprising non-crystalline drug
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135855A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8974827B2 (en) * 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US9233078B2 (en) * 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
CA3204372A1 (en) 2019-07-01 2021-01-07 Oakwood Laboratories, Llc System and method for making microspheres and emulsions
US20220361552A1 (en) * 2019-12-10 2022-11-17 Tyler White Particles Containing a Lipid Matrix Core and Active Ingredient

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE744162A (fr) * 1969-01-16 1970-06-15 Fuji Photo Film Co Ltd Procede d'encapsulage
CH594444A5 (es) * 1972-12-04 1978-01-13 Gerd Birrenbach
GB1413186A (en) * 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4489055A (en) * 1978-07-19 1984-12-18 N.V. Sopar S.A. Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use
DE2965725D1 (en) * 1978-07-19 1983-07-28 Patrick Couvreur Biodegradable nanoparticles, pharmaceutical compositions containing them and process for their preparation
US4272398A (en) * 1978-08-17 1981-06-09 The United States Of America As Represented By The Secretary Of Agriculture Microencapsulation process
DE2940676A1 (de) * 1979-10-08 1981-04-16 Krupp Polysius Ag, 4720 Beckum Anlage zur waermebehandlung von feinkoernigem gut
FR2515960A1 (fr) * 1981-11-06 1983-05-13 Alkhouri Fallouh Nazir Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application
US4798786A (en) * 1982-05-06 1989-01-17 Stolle Research And Development Corporation Living cells encapsulated in crosslinked protein
CH653553A5 (en) * 1982-11-01 1986-01-15 Sandoz Ag Microencapsulation process
US4670250A (en) * 1983-10-21 1987-06-02 Bend Research, Inc. Durable controlled release microcapsules
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
JPH02242826A (ja) * 1988-11-25 1990-09-27 Mitsui Petrochem Ind Ltd 塩素化エチレン・α‐オレフィン共重合体ラテックスの製造方法
US4990431A (en) * 1989-01-17 1991-02-05 Eastman Kodak Company Methods of forming stable dispersions of photographic materials
FR2660193B1 (fr) * 1990-04-03 1994-11-04 Philippe Maincent Produit opthalmique comportant des nanocapsules, son procede de preparation et utilisation des nanocapsules.
FR2660556B1 (fr) * 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.

Also Published As

Publication number Publication date
JP2542149B2 (ja) 1996-10-09
ATE150642T1 (de) 1997-04-15
EP0529711A1 (en) 1993-03-03
JPH0657005A (ja) 1994-03-01
US5705196A (en) 1998-01-06
ES2034891A1 (es) 1993-04-01
DE4128910A1 (de) 1993-02-11
EP0529711B1 (en) 1997-03-26

Similar Documents

Publication Publication Date Title
ES2034891B1 (es) Procedimiento de elaboracion en continuo de sistemas coloidales dispersos, en forma de nanocapsulas o nanoparticulas.
Dynarowicz-Łątka et al. Molecular interaction in mixed monolayers at the air/water interface
Alivisatos et al. Organization of'nanocrystal molecules' using DNA
KR0139215B1 (ko) 습윤와이프
FR2755136B1 (fr) Procede de preparation de nanoparticules de methylidene malonate, nanoparticules contenant eventuellement une ou plusieurs molecules biologiquement actives et compositions pharmaceutiques les contenant
DE69426568D1 (de) Verfahren zur umhüllung von nanopartikeln oder -tröpfchen
Braun et al. Influence of viscosity and solubilization on dissolution rate
DE69304065T2 (de) Herstellung und verwendung von, auf basis von cyclodextrin dispergierbaren kolloidal-systemen, in form von nanokugeln
FR2760641B1 (fr) Emulsion huile-dans-eau stable, son procede de fabrication et son utilisation dans les domaines cosmetique et dermatologique
JPH0940545A (ja) アスコルビン酸を含有する安定組成物
DE69015849T2 (de) Agrochemische und biozide Suspensionen.
Loftsson et al. The effects of cyclodextrins on transdermal delivery of drugs
FR2661414B1 (fr) Produit a base de keratines modifiees, son procede de preparation et les applications notamment en medecine humaine ou veterinaire.
FR2660554B1 (fr) Composition cosmetique ou dermo-pharmaceutique aqueuse contenant en suspension des spherouides hydrates d'une substance lipidique hydrophile.
ATE84710T1 (de) Verfahren zur herstellung von kolloidalen dispergierbaren proteinsystemen, wie nanopartikeln.
Loftsson et al. The influence of 2-hydroxypropyl-β-cyclodextrin on diffusion rates and transdermal delivery of hydrocortisone
GB1389238A (en) Process for encapsulating or coating finely divided materials by spray-drying-induced polymerisation
FR2425242A1 (fr) Dispositif destine a delivrer une substance chimique a un milieu contenant un liquide aqueux, son procede de production et son application a la lutte contre des vers parasites
Li et al. Organic-inorganic hybrid based on co-assembly of polyoxometalate and dopamine for synthesis of nanostructured Ag
Joo et al. Colloidal stability and in vitro permeation study of poly (ɛ-caprolactone) nanocapsules containing hinokitiol
Kim et al. Study of the adsorption behaviors of amphiphilic gold nanoparticles at the liquid–liquid interface dependent on surface properties
Egea et al. Penetration kinetics of cis-diamminedichloroplatinum (II) loaded nanoparticles in lipid monolayers as a membrane model of the reticuloendothelial system
RU96100511A (ru) Способ получения наночастиц и нанокапсул
TH32214A (th) ผลิตภัณฑ์ดูแลรักษาผิว
RU95119860A (ru) Иммунонаночастицы, несущие моноклональные анти-cd4-антитела, и их использование для профилактики и/или лечения патологических состояний, связанных с вич-инфекцией или в качестве биологических реагентов